Overview

A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects

Status:
Completed
Trial end date:
2018-08-22
Target enrollment:
Participant gender:
Summary
This is an 2-part study. Part 1 will assess the safety, tolerability and pharmacokinetics of single doses of FDL176 with and without co-administration of FDL169. Part 2 will assess the safety, tolerability and pharmacokinetics of repeated doses of FDL176 with and without co-administration of FDL169 .
Phase:
Phase 1
Details
Lead Sponsor:
Flatley Discovery Lab LLC